Rich Daniels has over 30 years of experience spanning the pharmaceutical and biotech sectors. He is an accomplished executive recognized for leadership and achievement across start-up ventures, mid-size companies, and Fortune 500 organizations. His expertise extends throughout all phases of product development, leading products and cross-functional programs from initial concept through to commercialization. He has experience in developing strategies, portfolio management, project planning, managing and integrating global functions, and leading large transformation initiatives
Rich most recently served as Chief Operating Officer at Primmune Therapeutics, a clinical-stage biotechnology firm, where he was accountable for developing and implementing the business strategy and leading cross-functional execution. Previous to Primmune, he was at Intercept Pharmaceuticals as Senior Vice President, managing clinical operations and R&D planning for their liver disease portfolio of small molecule FXR agonists. This included setting direction and leading the global clinical, quality, and program management functions. Before that Rich spent 15 years at Amgen, holding increasing leadership roles including Executive Director in the Oncology Therapeutic Area and R&D Quality Management, successfully leading staff and teams and contributing significantly to the strategic direction of the global oncology portfolio and enhancing regulatory compliance and quality systems. Earlier in his career, Rich was a Product Director at Genicon Sciences, leading commercialization activities for signal generation and detection systems, and as a clinical scientist at Agouron Pharmaceuticals with a focus on developing and executing Phase 1, Phase 2 and Phase 4 studies in both oncology and infectious disease. He began his career in the laboratory engaged in drug discovery and IND-enabling development activities.
University of California, San Diego, Bachelor of Science, Microbiology